Remove 2004 Remove Competition Remove Specialization
article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, Tysabri was performing well, having yielded $776 million in sales after being first approved in 2004, as per Biogen’s 2009 financial filings. However, new MS drugs like Novartis ’ Gilenya, were going to soon enter the market and increase competition within the MS therapeutic landscape.

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Founded 2004. BondLink is a fintech company specializing in the municipal bond market. Cybereason’s workplace culture is known to be fast-paced and competitive, with plenty of opportunities for learning. Salsify offers competitive benefits and a flexible vacation plan. Founded 2004. ClearCompany. 100-150 employees.

Sales 76
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Five potential EU regulatory changes impacting the life sciences industry in 2023

European Pharmaceutical Review

Key changes are expected to be proposed in relation to the Community Code on medicinal products, the EMA Regulation 726/2004 (the EU’s general pharmaceuticals legislation), the Orphan Regulation 141/2000 and the Pediatric Regulation 1901/2006.

Medical 117
article thumbnail

What Is Sports Medicine Medical Sales With Jordan Rawlins

Evolve Your Success

— Listen to the podcast here What Is Sports Medicine Medical Sales With Jordan Rawlins In this episode, we have with us another special guest. I did an internship and live with them for the summer in 2004 when I started a company. He goes by the name of Jordan Rawlins. That moves me. That’s how I’m wired.

article thumbnail

Uri Goren

Cadensee

48:12 What is Uri Gorenseeing that is special in the Israeli Digital Health ecosystem? When he was going through his cancer, he died in 2004. So, you see on one side, there's a special body of the FDA trying to listen to patients to find new targets for health and for pharmaceutical technology.